Viral hepatitis and fatty liver disease: how an unwelcome guest makes pâté of the host
- PMID: 18990087
- DOI: 10.1042/BJ20081916
Viral hepatitis and fatty liver disease: how an unwelcome guest makes pâté of the host
Abstract
HBV and HCV (hepatitis B and C viruses respectively) affect hundreds of millions of people globally, and are a major cause of chronic liver disease, including NAFLD (non-alcoholic fatty liver disease). Previous work on HCV-associated fatty liver disease has implicated two transcription factors that are important in lipid metabolism, SREBP1c (sterol-regulatory-element-binding protein 1c) and the LXRalpha (liver X receptor alpha). HBV-associated fatty liver disease has been less well-studied. New work from Kim and colleagues in this issue of the Biochemical Journal has provided new insight into how HBV causes fatty liver disease. Investigating HBV's so-called X gene product (HBx), they report that this viral protein directly binds to LXRalpha in the host liver cells to up-regulate the lipogenic transcription factor, SREBP1c. Also discussed in this commentary is another way that viruses such as HBV and HCV could induce SREBP1c-mediated lipogenesis, via the PI3K (phosphoinositide 3-kinase)-Akt signalling pathway.
Comment on
-
Hepatitis B virus X protein induces lipogenic transcription factor SREBP1 and fatty acid synthase through the activation of nuclear receptor LXRalpha.Biochem J. 2008 Dec 1;416(2):219-30. doi: 10.1042/BJ20081336. Biochem J. 2008. PMID: 18782084
Similar articles
-
Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARgamma.Gastroenterology. 2007 May;132(5):1955-67. doi: 10.1053/j.gastro.2007.03.039. Epub 2007 Mar 24. Gastroenterology. 2007. PMID: 17484888
-
Hepatitis B virus X protein induces lipogenic transcription factor SREBP1 and fatty acid synthase through the activation of nuclear receptor LXRalpha.Biochem J. 2008 Dec 1;416(2):219-30. doi: 10.1042/BJ20081336. Biochem J. 2008. PMID: 18782084
-
Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD).Drug Discov Today. 2007 Sep;12(17-18):740-7. doi: 10.1016/j.drudis.2007.07.009. Epub 2007 Aug 27. Drug Discov Today. 2007. PMID: 17826687 Review.
-
The role of the lipogenic pathway in the development of hepatic steatosis.Diabetes Metab. 2008 Dec;34(6 Pt 2):643-8. doi: 10.1016/S1262-3636(08)74599-3. Diabetes Metab. 2008. PMID: 19195625 Review.
-
Fat paradox of steatohepatitis.J Gastroenterol Hepatol. 2008 Mar;23 Suppl 1:S104-7. doi: 10.1111/j.1440-1746.2007.05294.x. J Gastroenterol Hepatol. 2008. PMID: 18336651 Review.
Cited by
-
NAFLD and HBV interplay - related mechanisms underlying liver disease progression.Front Immunol. 2022 Dec 5;13:965548. doi: 10.3389/fimmu.2022.965548. eCollection 2022. Front Immunol. 2022. PMID: 36544761 Free PMC article. Review.
-
Infections at the nexus of metabolic-associated fatty liver disease.Arch Toxicol. 2021 Jul;95(7):2235-2253. doi: 10.1007/s00204-021-03069-1. Epub 2021 May 24. Arch Toxicol. 2021. PMID: 34027561 Free PMC article. Review.
-
Association between nonalcoholic fatty liver disease and inflammatory periodontal disease: A case‑control study.J Indian Soc Periodontol. 2021 Jan-Feb;25(1):47-54. doi: 10.4103/jisp.jisp_45_20. Epub 2020 Sep 21. J Indian Soc Periodontol. 2021. PMID: 33642741 Free PMC article.
-
Thin Patient, Fatty Liver.Cureus. 2019 Feb 26;11(2):e4139. doi: 10.7759/cureus.4139. Cureus. 2019. PMID: 31058022 Free PMC article.
-
Interactions of Hepatitis B Virus Infection with Nonalcoholic Fatty Liver Disease: Possible Mechanisms and Clinical Impact.Dig Dis Sci. 2015 Dec;60(12):3513-24. doi: 10.1007/s10620-015-3772-z. Epub 2015 Jun 26. Dig Dis Sci. 2015. PMID: 26112990 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
